OMB# 0925-0648 Exp: 06/31/2024

Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

Thank you for providing your feedback on your experiences with NIH StrokeNet. NINDS is conducting this survey of NIH StrokeNet participants to assess satisfaction with service delivery by the network and NINDS; to determine the extent to which participants feel the network has facilitated the development and conduct of high-quality, multi-site clinical trials focused on key interventions in stroke prevention, treatment and recovery; and to obtain feedback relevant to program improvement.

Your participation in this survey is voluntary. Please note that your responses will not be identified with you personally or with your organization; survey results will be reported only in aggregate or deidentified form. NINDS does not plan to publish results of this survey but will use the responses received to inform future program improvements. If you have questions about the survey, or if you have any technical difficulty accessing or responding to the survey, please contact Dr. Cristina Nigro (cristina.nigro@nih.gov).

\* 1. Within which component of the network are you based? Select all that apply to your current or past participation in the network.

National Coordinating Center (NCC)

National Data Management Center (NDMC)

Regional Coordinating Center (RCC)

Satellite Site/Clinical Performance Site (SS/CPS)

Protocol Awarded Center (Non-Network)

None of the above

* 2. What is your role within the network? Select all that apply.	
Center or Site Principal Investigator (PI), Co-Principal Investigator, or Co-Investigator (Co-PI/Co-I)	
Study/Trial Principal Investigator (PI), Co-Principal Investigator, or Co-Investigator (Co-PI/Co-I)	
Center or Site Project Manager or Coordinator	
Study/Trial Project Manager or Coordinator	
Other Clinical or Support Staff	
Fellow or Student (Postdoc, Predoc, Clinical Research Fellow, Other Student or Trainee)	
Working Group member	
Other Network Committee member	
Other (please specify)	
3. Which domain of NIH StrokeNet trials have you been involved with? Select all that apply	<u>'</u> .
Acute intervention trials (DEFUSE 3, FASTEST, iDEF, MISTIE III, MOST)	
Prevention trials (ARCADIA, ARCADIA CSI, ASPIRE, CREST-2, CREST-H, SATURN, Sleep SMART)	
Recovery and rehabilitation trials (I-ACQUIRE, Telerehab, TRANSPORT2)	

## Overall network goals

4. What additions, removals, or changes to how the network is organized or managed would increase your satisfaction with the network's services and operations? Please list the top 3.

1.	
2.	
3.	

5. Some of the goals from the original Funding Opportunity Announcements (FOAs) for the network are listed in the table below. Please indicate your satisfaction with how the network as a whole has addressed each of these goals:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Support for high-quality, multi-site trials and clinical studies	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Efficient execution of clinical trials and studies	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Develop a stable infrastructure and research capacity that integrates expertise and collaboration across different subspecialties in stroke	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Research training and career development for clinical investigators	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

#### Network portfolio

6. Please indicate your satisfaction with the extent to which the network conducts important studies that are improving or will lead to improvements in stroke prevention, treatment, and rehabilitation in the next 10 years.

$\bigcirc \bigcirc $	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

7. Currently, the number of trials approved and being conducted in the NIH StrokeNet are:

Too few	Just right	Too many	No opinion
$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

8. Please indicate your satisfaction with each of the following items related to the network's support for a balanced portfolio of high-quality, multi-site trials and clinical studies:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Number of studies focused on adult populations	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Number of studies focused on pediatric populations	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Range of intervention types (across prevention, acute treatment, and rehabilitation trials)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Promotion and development of a pipeline for potential future trials for the network	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Management of trials that compete for the same patient groups	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Commitment to consider all eligible stroke patients for trial inclusion	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

9. What (if anything) would you want to see done differently related to best supporting a balanced portfolio of studies?

10. NINDS seeks to support clinical networks that are open to all researchers with great ideas for new clinical studies. Please indicate your satisfaction with each of the following items related to the extent to which the network encourages investigators <u>within the network</u> and <u>outside the network</u> to **submit proposals**:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
The network encourages investigators <u>within the</u> <u>network</u> to submit proposals	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
The network encourages investigators from the research community <u>outside the network</u> to submit proposals	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

11. Please indicate your satisfaction with each of the following items related to the extent to which the network encourages innovative study designs and approaches:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
The network supports the application of a variety of innovative study designs and approaches	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
The network engages investigators with relevant expertise from <u>within the network</u> in trial design and implementation	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
The network engages investigators with relevant expertise from <u>outside the network</u> in trial design and implementation	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

12. What (if anything) could the network do to encourage and enable innovation?

#### Study execution and efficiency

13. Please indicate your satisfaction with the network on each of the following items related to efficient execution of clinical trials and studies:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Time from initial study proposal to funding (pre- award)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Time to study start-up after notice of funding (post- award)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Participant enrollment	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Participant retention	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Study procedures execution	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Data quality	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Study monitoring	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

14. What (if anything) would you change to improve the efficiency of the network in executing clinical trials and studies?



15. Please indicate your satisfaction with the network in facilitating sharing best practices in enrolling and retaining diverse participants across the following demographic characteristics:

	Very				Very	
	dissatisfied	Dissatisfied	Neutral	Satisfied	satisfied	No opinion
Sex/gender	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Sexual and gender minorities	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Race/ethnicity	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Geographic distribution, including rural areas	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Socioeconomic status	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

16. In what ways could the network improve in facilitating enrollment and retention of diverse participants?

# Proposal submission

\* 17. If you are an investigator who has submitted a proposal for a NIH StrokeNet trial, have you ever withdrawn a proposal or grant application or chosen not to resubmit an unfunded application?

O Yes

- 🔘 No
- 🔿 N/A

18. Why did you withdraw or choose not to resubmit your application for a NIH StrokeNet trial? Select all that apply.

I needed more preparation
The network wasn't the right fit
The network didn't provide adequate support for preparing my application for resubmission
I chose to pursue other research directions
The timeline for resubmitting did not fit my needs
I found support elsewhere
Other (please specify)

#### Support from the network coordinating centers

19. Please indicate your satisfaction with the network on the following functions and activities it supports during the **conceptual phase** (i.e., all activities leading up to grant submission) of potential trials funded by NINDS:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Contribute to the development of new projects for submission	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Assessment of recruitment feasibility of a new study	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contribute to the development of the study timeline	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contribute to the development of the study budget	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contribute to the successful submission and approval of IND/IDE's	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Statistical design support provided by the NDMC	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

20. Please indicate your satisfaction with the network on the following functions and activities it supports during the **planning phase** (i.e., all activities from notice of funding approval to study start date) of trials funded by NINDS:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Rapid review and approval of new studies or amendments by the NCC cIRB	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Rapid review and approval of new studies or amendments by the commercial Advarra cIRB	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contribute to the selection of performance sites for new trials	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contribute to the development of plans to enhance the diversity of participant enrollment in network trials	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Effectively manage competing enrollment between trials	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contribute to the development of the data management and monitoring plan	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

21. Please indicate your satisfaction with the network on the following functions and activities it supports during the **implementation phase** (i.e., all activities from study start to study completion) of trials funded by NINDS:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Contribute to the rapid initiation of new trials	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Assistance with participant enrollment and retention in network trials	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Efficiently use the Master Trial Agreement to reimburse sites for study activities	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Effective and efficient use of the NCC central pharmacy	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Assurance of safety monitoring and monitoring site performance	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Efficient and effective use of the NDMC centralized data management system	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Assurance of data quality	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Statistical oversight provided by the NDMC	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Support with analysis, publication, and dissemination of results	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

22. What (if anything) would you want to see done differently related to how the network provides support during the **conceptual, planning, and/or implementation phases** of trials funded by NINDS?

23. How satisfied are you with the quality of NIH StrokeNet communication and collaboration activities among network components and investigators?

Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

24. What (if anything) would you want to see done differently related to how the network supports communication and collaboration among network components and investigators?

# Training activities

\* 25. Have you participated in any training and/or professional development activities as part of the NIH StrokeNet?

🔵 Yes

🔿 No

## Training activities

26. Please indicate your satisfaction with the network in each of the following items related to research training and career development for clinical investigators:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	N/A
StrokeNet Journal club	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
StrokeNet Educational webinars	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
StrokeNet Professional development webinars	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

#### 27. What (if anything) would you want to see done differently in terms of training activities provided for:

New clinical investigators	
RCC StrokeNet fellows	
Trial PIs	
Site PIs	
Network coordinators and other staff	

## Community engagement

28. Please indicate your satisfaction with the network in each of the following items related to community engagement:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	No opinion
Engages patient communities in identifying study areas ripe for answering important questions	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Engages research communities across disciplines in identifying study areas ripe for answering important questions	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Engages patient communities in developing study designs	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Engages research communities across disciplines in developing study designs	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Engages patient communities for support in participant enrollment and retention	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Engages patient communities in reviewing and interpreting results	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Engages patient communities with diverse gender, race/ethnic, geographic, and other medically underserved backgrounds	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Enables partnerships between other NIH networks, non-profit organizations, industry, and/or international researchers or organizations	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

29. What suggestions do you have for additional outreach or engagement with research and patient communities that would help the network achieve its goals?

## Support from NINDS

30. Please indicate your satisfaction with the following types of support you've received from NINDS program staff:

	Very dissatisfied	Dissatisfied	Neutral	Satisfied	Very satisfied	N/A
Pre-submission or pre-award support (e.g., concept development, proposal development, IRB and council review, etc.)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Post-award/study execution support (e.g., milestone development, monitoring, progress reporting, etc.)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

31. What (if anything) would you want to see done differently related to support you've received from NINDS program staff? Are there other support services that NINDS program staff could have provided that would have facilitated your network-related activities?

#### Lessons learned

32. We would like to know about any **positive aspects** of your involvement in the network that you consider important to the functioning, impact, or success of the network that we may not capture from other areas of this survey. Please include any details, anecdotes, or stories about anything you might wish to share about things like the benefits of participating in the network, the impact it has had on your research or career, etc. Please note that all answers on this survey are secure to the extent permitted by law.

33. It is also important for us to know about any **negative aspects** (concerns, problems, issues) of your involvement in the network that you consider important to the functioning, impact, or success of the network. Please note that all answers on this survey are secure to the extent permitted by law.

# Follow-up (optional)

34. Would you be willing to participate in a follow-up interview or group discussion? Please note that your survey responses will remain secure to the extent permitted by law, regardless of your answer to this question.

O Yes

🔵 No

35. Please provide your email address so that we may contact you about scheduling a follow-up interview or group discussion.

Email Address